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a b s t r a c t
A nanoparticle drug carrier system has been developed to alter the cellular uptake and chemotherapeutic
performance of an available chemotherapeutic drug. The system comprises of a multifunctional gold
nanoparticle based drug delivery system (Au-PEG-PAMAM-DOX) as a novel platform for intracellular
delivery of doxorubicin (DOX). Spherical gold nanoparticles were synthesized by a gold chloride reduc-
tion, stabilized with thiolated polyethylene glycol (PEG) and then covalently coupled with a polyami-
doamine (PAMAM) G4 dendrimer. Further, conjugation of an anti-cancer drug doxorubicin to the
dendrimer via amide bond resulted in Au-PEG-PAMAM-DOX drug delivery system. Acellular drug release
studies proved that DOX released from Au-PEG-PAMAM-DOX at physiological pH was negligible but it
was significantly increased at a weak acidic milieu. The intracellular drug release was monitored with
confocal laser scanning microscopy analysis. In vitro viability studies showed an increase in the associ-
ated doxorubicin cytotoxicity not attributed to carrier components indicating the efficiency of the dox-
orubicin was improved, upon conjugation to the nano system. As such it is postulated that the
developed pH triggered multifunctional doxorubicin-gold nanoparticle system, could lead to a promising
platform for intracellular delivery of variety of anticancer drugs.
 2017 Elsevier B.V. All rights reserved.
1. Introduction
Cancer is the second most common cause of death worldwide
with 14.1 million new cancer cases and 8.2 million deaths in
2012, compared with 12.7 million new cases and 7.6 million
deaths in 2008 [1,2]. In spite of all available advanced technology
for cancer treatment, chemotherapy is regularly accompanied by
an off-target effect on healthy tissues and limits the dose levels
of the drug below the therapeutic window to minimize patient dis-
comfort [3]. Generally, nanoparticle based drug delivery systems
are developed by the incorporation of active drugs via encapsula-
tion, conjugation or entrapment to a nanoparticle [4–6]. Despite
treatment advancements, the development of efficient nanoparti-
cle drug delivery system carrying anticancer drug for chemother-
apy has been a top priority in bionanotechnology field due to
their potential to selectively accumulate at tumor sites [7]. A tar-
geted drug delivery system may improve the efficacy of
chemotherapy via passive targeting due to an enhanced permeabil-
ity and retention (EPR) effect and could avail of an active targeting
system due to receptor-mediated endocytosis mechanism [8–10].
The accumulation of nanoparticles based on their size distribution
at tumor sites by extravasation through could also be available tar-
geting vascular defects in cancer cells, this concept known as the
enhanced permeability and retention (EPR) effect [11]. In the past
years, various pH, reduction and temperature responsive drug
delivery systems have been developed to trigger the drug release
in tumor cells [12,13].
In this study, we have developed a gold nanoparticle based drug
delivery nano-system to alter the intracellular drug release of dox-
orubicin (DOX) in vitro via an EPR effect. Due to the biocompatibil-
ity and unique optical, physical, and electronic properties of gold
nanoparticles (AuNPs) they are extensively used for targeted drug
delivery in biomedical nanotechnologies [14,15]. It has also been
reported that the intracellular drug delivery site can be monitored
using surface enhanced Raman scattering (SERS) due to the surface
plasmon resonance properties of the AuNPs [16,17]. AuNPs are
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often modified with polymers such as poly(ethylene glycol) (PEG)
to improve its stability without altering its associated biocompat-
ibility but simultaneously improving its potential in applications
in the biomedical field [18–20]. In general, the presence of the
PEG polymer is known to enhance the stability of colloidal AuNPs
by increasing the electrostatic repulsion between the nanoparticles
[21]. The conjugation of a PEG polymer to AuNPs has also been
shown to increase the accumulation of AuNPs at tumor sites
in vivo by increasing circulation time of nanoparticles in the blood-
stream [22]. As such PEG surface conjugation could also help to
prevent adverse effects and lower the uptake of spherical AuNPs
by the reticuloendothelial system (RES) during circulation in the
bloodstream [23,24]. The overall efficacy of drug delivery system
depends upon drug loading capacity of nanoparticles, dendrimers
are useful for simultaneous conjugation drugs and targeting
ligands and their structures offer the potential to increase the drug
loading capacity due to its highly branched nature, 3-D spherical
morphology, surface multi-functionality and well-defined compo-
sition [3,25–29].
Strumina et al. described the use of a nanoparticle-cored den-
drimer to design platforms for drug delivery nanosystems [30],
we report a novel pH-responsive PEGylated dendrimer modified
drug conjugated AuNPs as a smart drug delivery system for
chemotherapeutic purpose. Currently reports on the combined
use of a PEG polymer and PAMAM dendrimers with doxorubicin
for cancer therapy [31,32] are lacking in literature and little detail
into their interactions in vitro are discussed. Huang et al. have stud-
ied the intracellular behavior of nanoparticles using confocal laser
scanning microscopy (CLSM) to develop the nanoparticle based
drug delivery systems [33]. Li et al. described photothermal-
chemotherapy using PEGylated dendrimer-doxorubicin conjugated
gold nanorod drug delivery system [34]. This system required a lin-
ker to conjugate doxorubicin with five steps, in the present study
the nanosystem was synthesized in four steps without the aid of
a linker but using a modified PEG as a stabilizing agent. We
describe the synthesis of Au-PEG-PAMAM-DOX conjugate as a drug
delivery vehicle and tracking of intracellular drug release using
confocal laser scanning microscopy (CLSM) images.
2. Experimental section
2.1. Materials and chemicals
Gold(III) chloride trihydrate (HAuCl43H2O), trisodium citrate
dehydrate, 1-ethyl-3-(3-dimethylaminopropyl) carbodimide
(EDC) HCl, N-hydroxysulfosuccinimide (NHS), O-(benzotriazol-1-
yl)- N,N,N0,N0-tetramethyluronium hexafluorophosphate (HBTU),
diisopropyl ethylamine (DIPEA) and doxorubicin hydrochloride
(DOX) were purchased from Sigma Aldrich (Dublin, Ireland).
PAMAM dendrimer succinamic acid 10% in water solution (G4,
MW 20615) was purchased from Dendritech In. (USA), thiolated
PEG (SH-PEG-NH2) MW 5 kDa was purchased from Laysan Bio
Inc. (USA). Cell culture media, all supplements, Fetal Bovine Serum,
L-Glutamine, Streptomycin, trypsin, 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl tetrazolium bromide (MTT) were purchased from
Sigma Aldrich Ltd. (Ireland). NucRed Live 647 ReadyProbes were
purchased from Biosciences (Ireland). Phosphate buffered saline
tablets were purchased from Fisher Scientific UK ltd. (Leicester-
shire, UK). Ultrapure deionized water (resistivity greater than
18.0 MX cm1) was employed throughout the study.
2.2. Synthesis of gold nanoparticles (AuNPs)
Briefly, 100 ml of 1 mM HAuCl43H2O solution was brought to
the boil with vigorous stirring and 8 ml of 38.8 mM sodium citrate
was added, there was a resultant color change of the solution from
pale yellow to deep red. Boiling was continued for 10 min, after
which heating was removed and the solution stirred for a further
15 min [35]. The produced nanoparticles were stored at 4 C until
required.
2.3. Functionalization of AuNPs with PEG thiol compound
To functionalize the AuNPs, in a 30 lM of 70 ml AuNPs solution,
1 lM of 1 ml SH-PEG-NH2 (MW 5 kDa) was added and the solution
was stirred for a further 15 min. Then the mixture was kept at 4 C
overnight to react [21]. The solution was then dialyzed using a
dialysis membrane (MWCO 30 kDa) to remove the unreacted
PEG, the sample was washed three times with ultrapure water
and the purified product stored at 4 C.
2.4. Colloidal stability of thiolated Au nanoparticle (Au-PEG) based on
pH and salt test
UV-absorption spectroscopy was used to study the effect of
change in pH and NaCl concentration on colloidal stability of Au-
PEG in aqueous environment [21]. A series of pH solutions were
prepared by adding NaOH or HCL to the buffer solution (pH 7.4).
The stock solution, 1 phosphate buffer solution (pH 7.4) was pre-
pared by dissolving one phosphate buffered saline tablet in 100 mL
of ultrapure water. A series of NaCl solutions based on concentra-
tion were prepared by dilution of 1 M stock solution of electrolyte.
NaCl (1 M) stock solution was prepared by dissolving 0.5844 g
sodium chloride in 10 ml of ultrapure water.
2.5. Modification of Au-PEG with carboxylated PAMAM G4 dendrimer
To modify the Au-PEG NPs, a water solution of PAMAM-COOH
(2 ml, 2 mg) was mixed with EDCHCl (1.78 mg) and NHS (1 mg),
and the solution was stirred for 30 min to activate the carboxylic
group of PAMAM at room temperature. This solution was then
added into the Au-PEG NPs solution (50 ml, 14 lM AuNPs conc.)
and was stirred for a further 48 h [36,37]. The solution was then
again dialyzed using dialysis membrane (MWCO 30 kDa) to
remove the unreacted PAMAM and stored at 4 C.
2.6. Conjugation of doxorubicin hydrochloride (DOX) with Au-PEG-
PAMAM NPs
The prepared Au-PEG-PAMAM NPs (30 ml) were stirred at 0 C
for 5 min, then HBTU (3.5 mg) and DIPEA (4.31 ll) were added
and stirring was continued for 10 min at 0 C. A solution containing
doxorubicin (1 ml, 2 mg) was added to the mixture and the reac-
tion was stirred for 48 h at room temperature protected from the
surrounding light [38]. The final solution was again then dialyzed
using a dialysis membrane (MWCO 30 kDa) to remove the free
DOX and stored at 4 C.
2.7. Drug conjugation efficiency
The efficiency of drug conjugation was calculated by a direct
method using the absorption of the DOX at 480 nm. Briefly, the
unknown drug concentration of the nano-carrier system was
determined using a calibration curve based on series of known
DOX concentrations. The drug conjugation efficiency was then cal-
culated using following equation,
Conjugation efficiency % ¼ amount of drug in micelle
total amount of drug in feed
 100%
ðEq: 1Þ
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2.8. Characterization of drug delivery system and its intermediate
The absorption measurements at 480 nm and fluorescence
measurements at 471 nm were carried out using a Spectramax
M3 multi-mode microplate reader (Molecular Devices, USA). The
hydrodynamic size, polydispersity index (PDI) and zeta potentials
of the nanoparticles were measured using Zetasizer Nano analyser
(Malvern Instruments, Worcestershire, UK). Scanning electron
microscopy analysis was performed using Hitachi SU 6600 FESEM
instrument. The SEM samples were prepared by spin coating of
nanoparticle solution onto prewashed silicon substrates at
1000 rpm for 20 sec and dried in air in a dust free environment.
TEM analysis was carried out using FEI Tecani F30, with an acceler-
ating voltage of 300 kV. The TEM images were obtained by placing
a drop of sample on a coated 400 mesh Copper grid and evaporated
in air at room temperature. The point resolution is 0.19 nm in TEM
mode. Confocal images were taken using Zeiss 510 (Oberkochen,
Germany) laser scanning microscope.
2.9. pH dependent in vitro drug release studies
The pH dependent drug release of DOX loaded Au-PEG-
PAMAM-DOX nanosystem was verified using a pH 4.0 citric acid
and a pH 7.4 phosphate buffer solutions and monitoring the DOX
release as a function of time for 96 h. Briefly, the Au-PEG-
PAMAM-DOX nano-system (200 ll) was loaded into a mini dialysis
kit (MWCO 25 kDa); the mini dialysis kit was then placed in 4 ml of
corresponding buffer solution and incubated at 37 C. 250 ll of
solution from each buffer was harvested overtime with subsequent
replacement of equal volume of fresh buffer at the different time
interval. The release of the DOX was then quantified by measuring
its absorbance using absorption spectroscopy at 480 nm and the
concentration of the released DOX estimated with the aid of a stan-
dard curve.
2.10. Cell culture
The A549 cell line (human lung adenocarcinoma) was pur-
chased from ATCC (ATTC. No.: CCL-185) and cultured in Roswell
Park Memorial Institute (RPMI) 1640 medium, supplemented with
10% fetal bovine serum (FBS), 45 IU ml1 penicillin and 45 IU ml1
streptomycin in a humidified 5% CO2 incubator at 37 C.
2.11. Time dependent cellular studies using confocal laser scanning
microscopy
A549 cells (0.5 ml) were seeded at a cell concentration of
1  105 cells/ml in to 35 mm glass bottom culture dishes and
allowed to attach the glass substrate for 3 h after which 1.5 ml fully
supplemented mediumwas added and the cells were incubated for
24 h. Cells were then exposed to both free DOX and Au-PEG-
PAMAM-DOX in a time dependent manner (4 h, 12 h and 24 h).
For this, the culture medium was removed and the cells washed
with 2 ml of PBS three times, cells were then exposed to the com-
pounds under test and incubated for the desired time point. After
the exposure was completed, the exposure solutions were
removed and washed again three times with PBS prior to staining.
The exposed and control cells were then stained with NucRed Live
647 ReadyProbes, the cells were then incubated for 20 min and
finally washed three times with PBS. After staining, the cells were
fixed by addition of Formalin solution onto the cells for 10 min.
After fixation, formalin solution was removed and the cells were
washed twice with PBS and imaged on a Cells were then imaged
in 2 ml of PBS by using CLSM. The nuclear region of the cells was
stained by NucRed ready probe with excitation at 633 nm, emis-
sion observed between 649 and 799 nm and DOX was excited by
488 nm, its emission recorded between 560 and 615 nm.
2.12. Cell viability assay
The cytotoxic evaluation of free doxorubicin, Au-PEG-PAMAM-
DOX, Au-PEG-PAMAM was monitored with the aid of the MTT
assay. For cytotoxicity measurements, A549 cells were seeded in
96 well plates (Nunc, Denmark) at a density of 1  105 cells/ml
for 24 h exposure, 4  104 cells/ml for 72 h exposures respectively,
in 100 ll of medium containing 10% FBS. Three independent exper-
iments were conducted and eight replicate wells were employed
per concentration per plate. Following 24 h of cell attachment,
plates were washed with 100 ll/well phosphate buffered saline
(PBS) and further treated with 100 ll/well of free doxorubicin
(1.25–10 lg/ml), Au-PEG-PAMAM-DOX (1.25–10 lg DOX/ml,
0.0875–0.7 nM AuNPs), Au-PEG-PAMAM (0.0875–0.7 nM AuNPs),
prepared in media for 24 h and 72 h respectively. After 24 h and
72 h exposure, the medium for the controls or test exposures were
removed, the cells were washed with PBS and 100 ll of freshly pre-
pared MTT in media (10 mg/ml of MTT in media without FBS) were
added to each well. After 3 h incubation, the medium was dis-
carded and the cells were rinsed with PBS and 100 ll of MTT fixa-
tive solution (DMSO) were added to each well and the plates were
shaken at 240 rpm for 10 min. The absorbance was then measured
at 595 nm in a microplate reader.
2.13. Statistical analysis
At least three independent experiments were conducted in trip-
licate for all experiments. Test results for each assay were
expressed as percentage of the unexposed control ± standard devi-
ation (SD). Control values were set at 100%. Difference between the
control and samples were evaluated using the statistical analysis
package GraphPad Prism 7.0 (GraphPad Software, Inc., USA). Statis-
tical significant difference was set at p < 0.05. Normality of data
was confirmed by one way analysis of variance (ANOVA) and Den-
nett’s multiple comparison tests. Cytotoxicity data for MTT assays
were fitted to a sigmoidal curve and four parameter logistic model
to calculate the IC50 values and they were reported as ±95% confi-
dence interval. IC50 were estimated using GraphPad Prism 7.0.
3. Results and discussion
3.1. Synthesis and characterizations of drug delivery system Au-PEG-
PAMAM-DOX
As stated, we have developed a pH-sensitive Au-PEG-PAMAM-
DOX nanosystem with the goal of modifying the cellular uptake
mechanism and enhancing the chemotherapeutic efficacy of DOX
at cancer sites in the acidic compartments (Fig. 1). The PEGylated
gold nanosphere PAMAM dendrimer-doxorubicin conjugate (Au-
PEG-PAMAM-DOX) was prepared through a multistep synthesis
process (Fig. 2). The colloidal gold nanoparticles (AuNPs) were pre-
pared using a citrate reduction method of gold chloride, AuNPs
have a strong affinity towards polymer functional groups such as
CN, NH2 and SH and can be stabilized with these polymers through
covalent bonding to the AuNPs. The produced citrate capped
AuNPs were then coated with a thiolated PEG polymer in order
to enhance its stability in water. Biocompatibility of the nanopar-
ticles is improved by modifying the surface of nanoparticle with
dendrimer molecule. After the PEG stabilization, the surface of
AuNPs modified with a carboxylated PAMAM G4 dendrimer
through amide linkage with the amine group of PEG polymer via
an EDC coupling reaction. Finally, the DOX was conjugated with
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the carboxylic acid group of the PAMAM through amide bonding
by using DIPEA as a base and HBTU as a coupling agent to obtain
the final Au-PEG-PAMAM-DOX carrier system (Fig. 2).
The nanosystem Au-PEG-PAMAM-DOX was fully characterized
by using UV–Vis absorption spectra to verify the successful conju-
gation of PEG-SH, G4-PAMAM dendrimer to AuNPs and loading of
doxorubicin drug on nanosystem. Fig. 3a shows the UV–Vis absorp-
tion spectra of AuNPs, Au-PEG, Au-PEG-PAMAM and Au-PEG-
PAMAM-DOX respectively. The red shift in the absorbance peak
of gold nanoparticles observed has been widely attributed to a
slight change in the refractive index of the local environment of
AuNPs manifesting itself as a red shift in the absorbance spectrum
[39]. As shown in Fig. 3a, after conjugation of the PEG, PAMAM and
DOX onto the surface of AuNPs there was a resultant in red shift of
longitudinal surface plasmon resonance band by 3 nm, 2 nm and
2 nm respectively. The shifts observed in the absorption spectrum
of AuNPs were deemed an indication of the successful conjugation
PEG, PAMAM and DOX onto the surface of AuNPs. The conjugation
efficiency was then verified by absorption spectroscopy monitor-
ing the 480 nm absorption peak of the DOX in Au-PEG-PAMAM-
DOX and comparing it to a standard curve and the average loading
efficiency was then found to be 48.75% (an average of n = 3
batches) DOX present in total in the nano-carrier solution.
The DOX loaded nano-carriers and DOX solution were also char-
acterized using fluorescence spectroscopy and compared to an
equivalent DOX concentration (10 lg/ml) as shown in Fig. 3b.
When compared with the fluorescence spectra of a free DOX solu-
tion, the fluorescence of the Au-PEG-PAMAM-DOX nano-system
Fig. 1. Schematic illustration of pH-responsive DOX-loaded gold nanoparticle based drug delivery system of (Au-PEG-PAMAM-DOX) and triggered drug release under
intracellular endo/lysosomal conditions.
Fig. 2. Synthesis scheme of Au-PEG-PAMAM-DOX nanosystem.
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also displayed the typical emission band from the DOX but it was
of reduced intensity (normalized by 2.47 multiplication) such a
reduction in the fluorescent emission intensity of the bound DOX
would also further support successful conjugation to the PAMAM.
As observed in Fig. 3b the DOX loaded nano-carriers emission also
displays a red shift similar to that observed in the absorbance spec-
trum. However, there is an intensity decrease in the lower wave-
length region and an enhancement in higher wavelength, these
reductions could be due to aggregation of the nano-system (self-
absorption effect) [12] but are more like due to the conjugation
of the DOX to the PAMAM suppressing its emission. This coupled
with the absorption spectroscopy indicates that the DOXmolecules
had indeed bound successfully with the surface of gold nanoparti-
cle, giving confirmation of the formation of the DOX loaded nano-
carrier.
Further supportive evidence for the successful formation of the
nano-carrier was found in the zeta potential analysis of the sample,
Fig. S1a shows the zeta potential values obtained for the Au-PEG-
PAMAM-DOX nano-system at the different synthesis stages. The
zeta potential of Au-PEG (average value 14.9 ± 0.9 mV) became
more positive after conjugation with Au nanoparticles (average
value 34.43 ± 1.5 mV). The neutral PEG is shielded the negative
charge of the gold nanoparticles and offsets its charge [18]. As
the more neutral PEG is bonded with AuNPs, the negative charge
of AuNPs converted into a positive charge of Au-PEG nanoparticle.
After functionalisation of Au-PEG with negatively charged PAMAM
G4 dendrimer, surface zeta potential changed to an average value
of 14.47 ± 1.32, indicating that there was a covalent conjugation
of the carboxylic groups of PAMAM dendrimer with the amino
groups of the Au-PEG by an EDC coupling reaction. Changes in
the surface zeta potential of Au-PEG-PAMAM-DOX (average value
10.69 ± 1.32) due to the conjugation of positively charged dox-
orubicin indicating a successful loading of the DOX drug onto the
surface of Au-PEG-PAMAM nanoparticles.
The particle size of Au-PEG-PAMAM-DOX nanosystem was fur-
ther characterized by transmission electron microscopy (TEM) and
scanning electron microscopy (SEM) as shown in Fig. S1b and
Fig. S1c. TEM and SEM micrographs of nanocarrier indicated the
size of the nanoparticle around 20–25 nm. The hydrodynamic
diameter of all nanoparticles measured using dynamic light scat-
tering. As shown in the Table S1, the mean diameter of all nanopar-
ticles was smaller than 100 nm, with PDI of 0.4–0.6. Nanoparticles
with an average particle size of below 100 nm have been shown to
be more effective for the passive targeting of tumor sites [37].
At each stage of the synthesis, no agglomeration had occurred
but rather a systematic increase in the particle size due to the con-
jugation of PEG and the dendrimer to the system. As shown in
Fig. 3, there was no broadening of the absorption band of nanopar-
ticles observed. The PEG conjugation prevented the agglomeration
of gold nanoparticles by increasing the hydrophilicity of these
nanoparticles due to the formation of a hydrogen bond between
water molecule and conjugated PEG molecule [40]. The addition
of the dendrimers further helped to stabilize the nanoparticles
and prevent agglomeration [41]. As can be seen in the TEM and
SEM micrographs (Fig. S1b, Fig. S1c), the nanosystem Au-PEG-
PAMAM-DOX was completely dispersed in water and there was
no sign of agglomeration, this was further supported by the consis-
tent dispersibility of the system indicating no aggregation (Fig. S2).
3.2. Colloidal stability of Au-PEG nanoparticle in aqueous solution
The stability of a nanoparticle is a vital attribute for the success-
ful implementation of any potential nanosystem in drug delivery
application so extensive efforts were made to improve and verify
the stability of the produced materials in this study. As compared
with amine compounds, thiol compounds have a strong affinity for
AuNPs, which as a result forms stable Au-S covalent bonds [42].
Surface modification of AuNPs with thiolated PEG enhances the
biocompatibility of AuNPs, which can as was the case in this study
facilitates the further functionalization of nanoparticles with mul-
tiple other components such as dendrimers, antibodies and
enzymes.
The stability of the produced particles the effects of different
environment on the particles were monitored, initially the parti-
cles were placed into a NaCl solution with concentration range
from 0.02 to 0.1 M and the stability of AuNPs was monitored with
absorption spectroscopy. As the size of the nanoparticle increases,
the UV–vis absorption spectrum showed a red shift due to aggrega-
tion caused by shortening of the bond between the AuNPs [21]. As
shown in Fig. 4a, the absorption spectra of citrate capped gold
nanoparticle was noted to broaden at higher concentrations
(0.08 M and 0.1 M) such broadening of the absorption spectrum
is due to aggregation of nanoparticles in the salt solution, which
indicates its instability in a NaCl solution. When the absorption
spectra of Au-PEG were monitored, it did not display any peak
broadening or red shift in wavelength, as shown in Fig. 4b, indicat-
ing an increased stability when coated with the PEG, aggregation of
nanoparticles as was observed in the absence of the PEG. In this
study, as the concentration of NaCl solution was increased, the sur-
face charge of nanoparticle decreased and aggregation of nanopar-
ticle was observed, which is due to a reduction in the electrostatic
repulsion of the citrate capped AuNPs in the salt solution. The sta-
bility of AuNPs can be enhanced with an increase in the electro-
static repulsion and steric hindrance, when the citrate capped
AuNPs and thiolated AuNPs were compared, the presence of the
PEG-SH increases the steric hindrance around the AuNPs and
improves its stability in a salt solution [21].
Fig. 3. (a) UV–vis absorption spectra of Au-PEG-PAMAM-DOX nanosystem along with its intermediate product, (b) fluorescence spectra of DOX and Au-PEG-PAMAM-DOX
nanosystem.
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The stability of AuNPs as a function of pH was also monitored
by varying the pH over a range of 5.4–9.4. It was noted that the
AuNPs capped with PEG-SH did not exhibit any change in their
absorption spectrum over the tested range pH 5.4–9.4, as shown
in Fig. 4d. In contrast, the absorption spectrum of the citrate
capped AuNPs changed with pH, as shown in Fig. 4c indicating a
higher stability of the thiolated AuNPs in acidic as well as alkaline
environments when compared to the citrate capped AuNPs.
3.3. Acellular DOX release study
The ultimate desire of any nano-carrier is to release the payload
(drug) in a controlled fashion as such the kinetics of Au-PEG-
PAMAM-DOX drug delivery system was monitored by a dialysis
method. The nano-system was incubated in a physiological pH
(pH 7.4) buffer solution and an acidic (pH 4.0) buffer solution to
mimic cellular lysosomal compartments in vitro. Fig. 5 shows the
DOX release profiles from Au-PEG-PAMAM-DOX at pH 7.4 and at
pH 4.0 as a function of time. There was negligible release of the
DOX from Au-PEG-PAMAM-DOX at pH 7.4 conditions. In contrast,
we observed an approximately 50% DOX release from the nanosys-
tem after 96 h at pH 4.0 which we postulate is due to cleavage of
the amide bond between the DOX and dendrimer. The release pro-
file data demonstrated that there was a higher drug release from
nanoparticles and more importantly the drug was released in a
controlled manner over 96 h at pH 4.0. When compared to that
of a physiological pH 7.4, as such the produced system shows great
potential for further development in targeted applications.
To understand the drug release kinetics, the release data were
fitted with zero order kinetics model at pH 4. For slow drug release
kinetics, zero order model is more useful [27]. Release kinetics
were analyzed by plotting the release data vs. time by using fol-
lowing equation,
Qt ¼ Q0 þ K0t ðEq: 2Þ
where Qt is the amount of drug dissolve in time t, Q0 is the initial
amount of drug in the solution, K0 is the release constant. The value
of K0 was determined to be 0.2083 (R2 = 0.9618). Conclusively, drug
was slowly released through nanocarrier due to cleavage of amide
bond in the acidic condition.
3.4. Cell viability study
The in vitro cytotoxicity was evaluated by the MTT assay, for
free doxorubicin, Au-PEG-PAMAM and Au-PEG-PAMAM-DOX were
all calculated and the component parts of the Au-PEG-PAMAM-
DOX system used as reference for the produced nano-system in
order to evaluate if the overall system was more effective than
the free DOX. All compounds were tested over a concentration
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Fig. 5. pH dependent percentage release of DOX using Au-PEG-PAMAM-DOX
nanosystem.
Fig. 4. UV–vis absorption spectra of AuNPs capped with (a) citrate, (b) PEG-SH in solution of different NaCl concentration, UV–vis absorption spectra of AuNPs capped with (c)
citrate, (d) PEG-SH in different pH solutions.
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range of 1.25–10 lg/ml (or DOX equivalent AuNPs concentration)
and were exposed to the A549 cells for periods of 24 h and 72 h.
As can be seen in Fig. 6, Au-PEG-PAMAM-DOX, free DOX and
Au-PEG-PAMAM exhibited both a dose and time dependent cyto-
toxicity profiles. The Au-PEG-PAMAM was noted to have little
effect on cells and caused a statistically significant reduction in via-
bility, it was deemed of lowmagnitude and to be due to conjugated
PAMAM dendrimer [43,44] on the surface of the material. The cell
viability was noted to decrease as a function increased exposure
time and was verified by the decreasing IC50 values as a function
of exposure time as shown in the Table S2. Interestingly the Au-
PEG-PAMAM-DOX exhibited a higher cytotoxicity than free DOX
and Au-PEG-PAMAM nanoparticles indicating that the final system
improves the efficacy of the DOX. The Au-PEG-PAMAM-DOX
yielded an IC50 value of 1.79 lg/ml significantly lower than that
of the free DOX, which yielded a value of 4.0 lg/ml and the Au-
PEG-PAMAM yielding an IC50 of 24.5 after 24 h exposure. In terms
of cell viability levels the Au-PEG-PAMAM-DOX induced 69.76%
Fig. 6. In vitro cytotoxicity of A549 cells treated with different concentrations of Au-PEG-PAMAM-DOX, free DOX and Au-PEG-PAMAMmaterials after [A] 24 h and [B] 72 h of
incubation. Data is expressed as percentage of control mean ± SD of three independent experiments ** denotes statistically significant difference from the unexposed control
(P < 0.05).
Fig. 7. CLSM images of intracellular DOX release using Au-PEG-PAMAM-DOX nanosystem. Materials were incubated with A549 cells for 4 h, 12 h and 24 h and fixed using
formalin and washed, followed by CLSM observation. Green fluorescence is associated with NucRed with excitation at 633 nm, emission at 649–799 nm, the red fluorescence
is showed by free DOX and released DOX with excitation at 488 nm and emission at 560–615 nm.
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cell death when compared to 58.40% cell death induced by free
DOX equating to an approximately 12% increase in the efficacy of
the DOX (Fig. 6A). After 72 h exposure, the Au-PEG-PAMAM-DOX
gave an IC50 of 0.31 lg/ml compared to a value of 0.40 lg/ml for
the free DOX and 14.9 lg/ml for the Au-PEG-PAMAM. While the
difference in the viability levels were not so apparent after longer
exposures the results suggest that the creation of the nano-carrier
system could significantly alter the speed at which the DOX kills
the cell as evident by the differing IC50 values in the 24 h
exposures.
3.5. In vitro confocal imaging
Drug release and accumulation in vitro was monitored with the
aid of confocal laser scanning microscopy coupled with counter
staining the nucleus of the A549 cells and monitoring the site of
DOX accumulation by tracking the DOX emission as shown in
Fig. 7. It has been reported that PEGylated dendrimer nanoparticles
are internalized into the cells by an EPR effect and reside within
the cell outside the nucleus most likely in the lysosomal compart-
ments of the cell [45]. In the study here free doxorubicin and DOX
conjugated nanoparticles showed different cellular uptake mecha-
nisms of the drug by the cells [46]. As can be seen in Fig. 7, after 4 h
incubation with the Au-PEG-PAMAM-DOX nanosystem, the drug
had accumulated in the lysosomal compartment of cells, indicated
by red fluorescence from DOX. These findings verify the results of
the acellular DOX release study, which confirmed that the drug
was released from the nano system at pH 4.0 (Fig. 5) and support
the hypothesis that we have synthesized a pH sensitive release sys-
tem for DOX. As incubation time increases to 24 h, the red fluores-
cence from DOX could be observed in the cell nucleus as well as in
the cytoplasm as shown in Fig. 7, indicating that the lower pH
value triggered the release of the DOX within the lysosomal com-
partment of the cell which subsequently left the lysosome and
accumulated in the nucleus. In contrast, internalization of DOX
was observed in the cells within 4 h incubation of free doxorubicin
with nuclear accumulation clearly visible in all the exposures up to
24 h as shown in Fig. 7. These findings clearly demonstrate that the
Au-PEG-PAMAM-DOX nanosystem released the DOX in controlled
manner; it entered initially in to the cytoplasm, accumulated in
the lysosomes and after 24 h lysosomal drug release occurred
and the drug entered into the cell nucleus. As such the produced
pH sensitive Au-PEG-PAMAM-DOX drug delivery system could sig-
nificantly enhance the efficacy of DOX by a controlled intracellular
drug release couple with effective targeting may also reduce
unwanted side effects, and may lead to a more efficient
chemotherapy treatment.
4. Conclusion
In conclusion, we have developed a promising platform for the
pH-responsive intracellular drug release in the acidic organelles of
cancer cells based on PEGylated PAMAM doxorubicin-gold (Au-
PEG-PAMAM-DOX) nanosystem. When compared to citrate coated
AuNPs, the PEG polymer coated AuNPs showed improved colloidal
stability and biocompatibility with low toxicity. The active agent
DOX was conjugated onto the final system with the aid of a den-
drimer via an amide bond. The final drug delivery system Au-
PEG-PAMAM-DOX showed a pH sensitive drug release, this was
subsequently shown to be true for in vitro studies as the nano-
carrier was shown to enter the cell through a different mechanism
and accumulate in the lysosomal compartments (pH 4–5) of the
cells. As such the DOX loaded Au-PEG-PAMAM-DOX nanoparticle
altered the cellular uptake mechanism of DOX which had an effect
on its associated cytotoxicity making the DOX more effective in
short term exposures. This novel multifunctional dendrimer based
PEGylated doxorubicin-gold nanoparticle (Au-PEG-PAMAM-DOX)
nano-system could provide a new platform for the intracellular
release of anticancer drug at the tumor sites.
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